From the Departments of Behavioral Science (L.C., P.A.P., Q.W.), Integrative Medicine Program (L.C.), Melanoma Medical Oncology (L.V., D.K., L.W., T.P., L.R.), and Urology (C.S., C.P., R.B., L.P.), The University of Texas MD Anderson Cancer Center, Houston, Texas; and the Department of Urology B.M.), Baylor College of Medicine, Houston, Texas.
Address correspondence and reprint requests to Lorenzo Cohen, PhD, Department of Behavioral Science—Unit 1330, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. E-mail: [email protected]
Received for publication April 28, 2010; revision received November 12, 2010.
This research was supported, in part, by Grant R01 MH59432 (Principal Investigator: Lorenzo Cohen) from the National Institute of Mental Health/National Cancer Institute. The Immune Monitoring Core Laboratory is funded, in part, by Grant NCI CA16672 from The University of Texas MD Anderson Cancer Center.
